Ensuring familiarity with the area
Pharmacy teams and individuals planning to use denosumab biosimilar for bone metastases in advanced cancer or giant cell tumours of the bone should prepare carefully. Read the following to understand where denosumab 120mg is currently recommended for use.
National guidelines
Ensure you are familiar with:
Where NICE has recommended the reference product (‘the originator’), the same advice will apply to the biosimilar medicine. Ensure you are familiar with local funding arrangements for denosumab 120mg.
Denosumab is not routinely commissioned for giant cell tumours of the bone as it is awaiting NICE TA publication for this indication. Ensure you are familiar with local treatment pathways and funding arrangements if denosumab 120mg is prescribed for this indication in your organisation.
Product characteristics
Xgeva (Amgen) is the denosumab 120mg reference product. Refer to the product information for the licensed indications and full prescribing advice. Xgeva is available as 120mg vial and a 120mg pre-filled syringe.
Changes with denosumab
Denosumab lost patent exclusivity in November 2025.
Denosumab 120mg biosimilars are available as a vial and pre-filled syringe presentation.
NHS Framework awards
The Medicines Procurement and Supply Chain (MPSC) web catalogue provides information about products available on NHS England procurement frameworks. Further information on procurement arrangements is available in the SPS article series, Procurement of medicines and services for NHS secondary care (SPS page).
The framework for this biosimilar was awarded regionally. The five biosimilars discussed in this article are available through NHS procurement framework arrangements.
Bomyntra (Fresenius Kabi) vial and pre-filled syringe
Product information available via MHRA website
Enwylma (Zentiva Pharma) vials
Product information available via MHRA website
Jubereq (Accord Healthcare) vials
Product information available via MHRA website
Osenvelt (Celltrion) vials
Product information available via MHRA website
Yaxwer vials (Gedeon Richter) vials
Product information available via MHRA website
Other 120mg denosumab biosimilars are licensed in the UK, full details can be found on the MHRA website.
Planning for implementation
Organisations should plan for implementation of best value denosumab product.
Pharmacy need to work collaboratively across the integrated care systems to plan for implementation and identify potential barriers. This will include collaboration with prescribing clinicians, specialist nurses, business managers, finance and contracting teams, pharmaceutical industry and homecare providers.
Early engagement with homecare teams and providers is essential.
Implementation checklist
Use our phase one implementation checklist to support planning.
Patient Information Sheet
SPS has produced a patient information sheet that can be adapted locally.
SPS resources on use of biosimilars
We have materials to help understand the background to biological and biosimilar medicines in general.
Understanding biological and biosimilar medicines
The licence and supporting evidence for denosumab 120mg biosimilars
SPS resources on denosumab 60mg biosimilars
We also have materials to support with the implementation of denosumab 60mg biosimilar.
SPS resources on pipeline medicines
Be aware of information on pipeline aflibercept biosimilars. Detail is available from:
Update history
- Streamlined to align with MPSC Framework
- Wording updated to reflect current situation.
- Updated with new licensed products: Bomyntra, Enwylma, Yaxwer.
- Published